Search

Your search keyword '"Levy-Bachelot, L."' showing total 192 results
Start Over Author "Levy-Bachelot, L."
192 results on '"Levy-Bachelot, L."'

13. Intérêt d'une approche géostatistique pour analyser les disparités géographiques de la couverture vaccinale contre les papillomavirus humains en France

Author

Ribassin-Majed, L., Pereira, M., Magneron, C., Levy-Bachelot, L., Fagherazzi, G., Baldauf, J.-J., Raude, Jocelyn, École des Hautes Études en Santé Publique [EHESP] (EHESP), Unité des Virus Emergents (UVE), and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Geostatistical model, Human papillomavirus vaccine, Vaccination coverage
Abstract

International audience; Background: The use of geostatistical methods remains rare in health studies. In order to assess the usefulness of the geostatistical approach in epidemiology, we chose to apply these methods to the vaccination coverage rate (VCR) against human papillomavirus (HPV) in France. Indeed, HPV vaccine coverage remains low in France and geographical disparities are sizable. The objective of this study was to identify the socioecological factors that may explain these geographical variations. Methods: Sociological, economic and behavioral data for 2016 have been gathered (demographics and public health database, web and social networks) and were correlated with the HPV VCR vaccine coverage over the French territory. Homogeneous geographical areas defined by strong correlations for groups of variables were selected. In each homogeneous area, principal component analysis was performed and a geostatistical approach provided an estimate predicting vaccine coverage at a given scale. Results: HPV VCR spatial variations in France cannot be fully explained by a single model. In urban areas, a low rate of HPV VCR is preferentially associated with unfavorable socioeconomic factors (poverty, unemployment, immigration). In rural areas, HPV VCR is preferentially associated with sociocultural factors (socio-professional categories, education level, interest in alternative medicines the anti-vaccine movement). Two secondary geographical areas were defined: the Île-de-France region and 12 departments in northeastern France. In the Île-de-France region, the association with the economic factors one again appears as in urban areas in general. The northeasteran departments represent a particular case insofar as HPV VCR is relatively high, notwithstanding economic poverty indicators. Conclusion: Geostatistical modeling successfully identifies new potential explanations for HPV VCR geographical disparities in France. These results could help to adapt or develop future vaccination programs in specific areas by taking into account the sociological, economic and behavioral characteristics of their population

Published
2021
Full Text
View/download PDF

15. Coût hospitalier de l’angioplastie artérielle pulmonaire par ballonnet (AAPB) : étude observationnelle à partir des données du programme de médicalisation des systèmes d’information (PMSI)

Author

Cottin, V., primary, Brenot, P., additional, Bensimon, L., additional, Raguideau, F., additional, Chaize, G., additional, Hakme, A., additional, Levy-Bachelot, L., additional, Vainchtock, A., additional, Dallongeville, J., additional, and Bouvaist, H., additional

Published
2021
Full Text
View/download PDF

17. PCV25 Hospital Costs of Balloon Pulmonary Angioplasty (BPA) Procedure and Management for Chronic Thromboembolic Hypertension Patients: An Observational Study Based on the French National Hospital Discharge Database (PMSI)

Author

Cottin, V., primary, Bensimon, L., additional, Raguideau, F., additional, Chaize, G., additional, Hakmé, A., additional, Levy-Bachelot, L., additional, Vainchtock, A., additional, Dallongeville, J., additional, Bouvaist, H., additional, and Brenot, P., additional

Published
2020
Full Text
View/download PDF

18. PCN81 Cost-Effectiveness Analysis of Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous CELL Carcinoma in Patients Whose Tumor Expressed Programmed Death-Ligand 1 at Combined Positive Score ≥1 in France

Author

Massetti, M., primary, Even, C., additional, Geoffrois, L., additional, Farge, G., additional, Levy Bachelot, L., additional, Borse, R., additional, Chirovsky, D., additional, and Durand-Zaleski, I., additional

Published
2020
Full Text
View/download PDF

23. Clinical and economic burden of head and neck cancer : a nationwide retrospective cohort study from France

Author

Schernberg, A., Sagaon Teyssier, Luis, Schwarzinger, M., Baillot, S., Bec, M., Benmahammed, L., Even, C., Geoffrois, L., Huguet, F., Le Vu, B., Levy-Bachelot, L., Luchini, S., Pointreau, Y., Robert, C., Temam, S., and Epicorl Study Group

Subjects
National Hospital discharge database, costs, prognosis, burden of disease, head and neck squamous cell carcinoma
Abstract

Objectives: To evaluate the clinical and economic burden of head and neck squamous cell carcinoma (HNSCC) in France. Methods: All 53,255 incident adult patients discharged with a first diagnosis of HNSCC in 2010-2012 were identified from the 2008-2013 French National Hospital Discharge (PMSI) database. We conducted a retrospective longitudinal analysis of prognosis and direct costs attributable to HNSCC. Results: Direct medical costs attributable to HNSCC care amounted to 665 million euros in 2012 in France. The majority (62%) of incident patients were 64 years old or less at HNSCC diagnosis and incurred 1.3-fold higher mean direct costs as compared to elderly patients (41,909 vs 32,221 euros over 3 years, respectively; p

Published
2019

24. Estimating health state utility from activities of daily living in the French National Hospital Discharge Database : a feasibility study with head and neck cancer

Author

Schwarzinger, M., Luchini, S., Baillot, S., Bec, M., Benmahammed, L., Even, C., Geoffrois, L., Huguet, F., Le Vu, B., Levy-Bachelot, L., Pointreau, Y., Robert, C., Sagaon Teyssier, Luis, Schernberg, A., Temam, S., and EPICORL Study Group

Subjects
Health state utility, EQ-5D-3L, National hospital discharge database, Cost-effectiveness analysis, Activities of daily living, Head and neck cancer, Item response theory, QALYs
Abstract

BackgroundHealth state utility (HSU) is a core component of QALYs and cost-effectiveness analysis, although HSU is rarely estimated among a representative sample of patients. We explored the feasibility of assessing HSU in head and neck cancer from the French National Hospital Discharge database.MethodsAn exhaustive sample of 53,258 incident adult patients with a first diagnosis of head and neck cancer was identified in 2010-2012. We used a cross-sectional approach to define five health states over two periods: three "cancer stages at initial treatment" (early, locally advanced or metastatic stage); a "relapse state" and otherwise a "relapse-free state" in the follow-up of patients initially treated at early or locally advanced stage. In patients admitted in post-acute care, a two-parameter graded response model (Item Response Theory) was estimated from all 144,012 records of six Activities of Daily Living (ADLs) and the latent health state scale underlying ADLs was calibrated with the French EQ-5D-3L social value set. Following linear interpolation between all assessments of the patient, daily estimates of utility in post-acute care were averaged by health state, patient and month of follow-up. Finally, HSU was estimated by health state and month of follow-up for the whole patient population after controlling for survivorship and selection in post-acute care.ResultsHead and neck cancer was generally associated with poor HSU estimates in a real-life setting. As compared to distant metastasis at initial treatment, mean HSU was higher in other health states, although numerical differences were small (0.45 versus around 0.54). It was primarily explained by the negative effects on HSU of an older age (38.4% aged >= 70years in early stage at initial treatment) and comorbidities (>50% in other health states). HSU estimates significantly improved over time in the relapse-free state (from 8 to 12months of follow-up).ConclusionsHSU estimates in head and neck cancer were primarily driven by age at diagnosis, comorbidities, and time to assessment of cancer survivors. This feasibility study highlights the potential of estimating HSU within and across severe conditions in a systematic way at the national level.

Published
2019

31. Coût du diabète de type 2 en France

Author

Charbonnel, B., primary, Simon, D., additional, Dallongeville, J., additional, Bureau, I., additional, Leproust, S., additional, Levy-Bachelot, L., additional, Gourmelen, J., additional, and Detournay, B., additional

Published
2016
Full Text
View/download PDF

34. Treatment Persistence with Golimumab in France

Author

Belhassen, M, primary, Hudry, C, additional, Woronoff, M, additional, Levy Bachelot, L, additional, Deschamps, C, additional, Ginoux, M, additional, van Ganse, E, additional, Fautrel, B, additional, and Tubach, F, additional

Published
2016
Full Text
View/download PDF

38. CO-04: Coût du diabète de type 2 en France

Author

Charbonnel, B., primary, Simon, D., additional, Dallongeville, J., additional, Bureau, I., additional, Leproust, S., additional, Levy-Bachelot, L., additional, Gourmelen, J., additional, and Detournay, B., additional

Published
2016
Full Text
View/download PDF

43. Real‐world treatment patterns and clinical outcomes in advanced cutaneous melanoma patients in France.

Author

Sassolas, B., Leccia, M. T., Godard, C., Benmahamed, L., Levy‐Bachelot, L., Flinois, A., and Bédane, C.

Subjects
MELANOMA, BRAF genes, IMMUNOTHERAPY, ANTINEOPLASTIC agents
Abstract

Abstract: Background: Since 2011, the management of advanced melanoma has radically changed with the availability of new therapies (immunotherapy and BRAF‐targeted therapy) and with BRAF testing. Objectives: Following the introduction of these new therapies, the objectives of this AMEL study were to describe treatment patterns and evaluate overall survival (OS) among unresectable stage III/IV melanoma patients, in a real‐life setting in France. Methods: The AMEL study is a multicentre retrospective record review study. Thirty‐three physicians working in 33 unique treatment centres participated in the study. Two hundred and sixty‐four patients diagnosed between 1 January 2012 and 31 October 2012 with unresectable stage III/IV melanoma were included in the study. Results: 94.7% of the patients received a first‐line antitumour drug treatment, 62.5% a second‐line treatment while 26.9% received a third‐line treatment with no significant differences between patients with a BRAF mutation (50.4%) and BRAF wild type (47.0%). First‐line treatment differs according to the BRAF status: 74.8% of patients with a BRAF mutation received a BRAF inhibitor while 79.3% of the BRAF wild‐type patients were treated with conventional chemotherapy. In second line and over, the treatment patterns were more heterogeneous, depending on the BRAF mutation, the treatment received previously, the speed of progression of the disease and the availability of immunotherapy at the time the treatment was initiated. Conclusion: Regardless of the BRAF mutation status, the median OS of patients was 16 months (95% CI = 14–18). Compared to a similar study conducted in 2007 (MELODY), a gain of 4 months is observed. The gain seems to be higher for patients with a BRAF mutation (18 months) than for those without a BRAF mutation (14 months). The OS of patients who sequentially received both a BRAF inhibitor and ipilimumab (28 months) highlights the benefit of this treatment sequence. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

44. Tolerance and durability of abacavir/lamivudine (ABC/3TC)‐containing regimens: results from a large prospective French cohort

Author

Cuzin, L, Allavena, C, Levy?Bachelot, L, Valantin, Ma, Mellliez, H, Pugliese, P, Poizot?Martin, I, Duvivier, C, Finkielsztejn, L, and Abel, S

Subjects
Histocompatibility testing -- Analysis, Antiviral agents -- Dosage and administration -- Complications and side effects, Allergy -- Testing, HIV patients -- Care and treatment, Health
Abstract

7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, Methods Patients (pts) were selected from the Dat'AIDS French prospective cohort if they were prescribed an ABC/3TC containing regimen for the first time between 01/01/2004 and 31/12/2007 and were still [...]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results